Login to Your Account

Hutchison's Epitinib passes BBB in lung cancer patients who have brain tumors

By Shannon Ellis
Staff Writer

Wednesday, December 7, 2016

SHANGHAI – Shanghai-based Hutchison Medipharma Co. Ltd. presented phase I data for epitinib at the World Conference on Lung Cancer in Vienna showing that epitinib is a safe EGFR inhibitor with the ability to cross the blood-brain barrier (BBB).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription